破解癌症免疫治療瓶頸！中國醫大研究團隊找到提升治療效果的新方向
日期：2026-10-22
資料來源：研究亮點｜洪明奇院士
分享：
破解癌症免疫治療瓶頸！中國醫大研究團隊找到提升治療效果的新方向
為什麼有些癌症免疫治療在動物實驗中效果顯著，進入人體臨床試驗後卻不如預期？
中國醫藥大學洪明奇院士率領研究團隊，在國際頂尖期刊《Science》發表重要研究成果，找到可能影響治療成效的關鍵原因。
研究發現，部分癌細胞因缺少一種名為「MTAP」的基因，會削弱人體辨識異常細胞、啟動免疫防禦的能力，使原本用來喚醒抗癌免疫反應的STING藥物難以發揮作用。
更重要的是，研究團隊發現，透過調節癌細胞的代謝途徑，搭配現有藥物DFMO，有機會重新提升腫瘤對STING治療的敏感度，增強免疫系統攻擊癌細胞的能力。
這項突破不僅為癌症免疫治療效果不佳提供新的科學解釋，也為未來依據患者基因特徵選擇治療方式、發展更精準的癌症免疫療法開啟新方向。
Breaking Through Barriers in Cancer Immunotherapy: CMU Researchers Identify a New Strategy to Improve Treatment Effectiveness
Why do some cancer immunotherapies show promising results in animal studies but fail to achieve the same effectiveness in human clinical trials?
A research team led by Academician Mien-Chie Hung of China Medical University (CMU) has published a significant discovery in the prestigious journal Science, identifying a key mechanism that may explain why certain cancer immunotherapies fail.
The study found that cancer cells lacking a gene called MTAP can weaken the body's ability to recognize abnormal cells and activate immune defenses. This makes tumors less responsive to STING agonists, a class of drugs designed to stimulate the immune system to attack cancer.
More importantly, the researchers discovered that targeting cancer cell metabolism with a drug known as DFMO may help restore tumor sensitivity to STING-based therapies, potentially strengthening the immune system's ability to fight cancer.
This breakthrough provides new scientific insights into resistance to cancer immunotherapy and opens promising avenues for developing more precise, personalized cancer treatments based on patients' genetic profiles.
原文網址: https://www.science.org/doi/10.1126/science.adl4089
相關圖片：
回前頁